Zuker MF Tablet PR is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. This dual-action formulation provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet and exercise alone. Zuker MF Tablet PR is designed for prolonged release, allowing for once-daily dosing, which may improve patient compliance. It is recommended to initiate therapy under medical supervision with appropriate dose titration based on glycemic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily related to Metformin, while hypoglycemia risk is associated with Gliclazide. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and hematological parameters is essential during treatment. Zuker MF Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.